Heterogeneity of monoclonal antibodies

Journal of Pharmaceutical Sciences

Volumn 97, Issue 7, 2008, Pages 2426-2447

  Liu, Hongcheng ^a   Caza Bulseco, Georgeen ^a   Faldu, Dinesh ^a   Chumsae, Chris ^a   Sun, Joanne ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Analytical biochemistry; Deamidation; Glycosylation; Protein aggregation; Stability; Structure

Indexed keywords

GLUTAMINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; MONOCLONAL ANTIBODY; OKT 3;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CROSS LINKING; CYCLIZATION; DEAMINATION; DISULFIDE BOND; DRUG CONFORMATION; ENZYME ACTIVITY; GLYCOSYLATION; ISOMERIZATION; OXIDATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; REVIEW; X RAY CRYSTALLOGRAPHY;

EID: 52449112071     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21180     Document Type: Review

References (259)

1. Askonas BA. 1961. A study on globulin formation by plasma-cell neoplasm (5563) transplantable in mice. Biochem J 79:33-43.
2. Awdeh ZL, Askonas BA, Williamson AR. 1967. The homogeneous-gamma-G- immunoglobulin produced by mouse plasmacytoma 5563 and its subsequent heterogeneity in serum. Biochem J 102:548-553.
3. Awdeh ZL, Williamson AR, Askonas BA. 1969. Heavy and light chains of a homogeneous immunoglobulin-G. FEBS Lett 5:275-278.
4. Awdeh ZL, Williamson AR, Askonas BA. 1970. One cell-one immunoglobulin. Origin of limited heterogeneity of myeloma proteins. Biochem J 116:241-248.
5. Latner L, Albert L, Marshall T, Gambie M. 1980. Michroheterogeneity of serum myeloma immunoglobulins revealed by a technique of high resolution two-dimensional electrophoresis. Electrophoresis 1:82-89.
6. Tracy RP, Currie RM, Kyle RA, Young DS. 1982. Two-dimensional gel electrophoresis of serum specimens from patients with monoclonal gammopathies. Clin Chem 28:900-907.
7. Jungbauer A, Tauer C, Wenisch E, Uhl K, Brunner J, Purtscher M, Steindl F, Buchacher A. 1990. Isolation of isoproteins from monoclonal antibodies and recombinant proteins by chromatofocus-ing. J Chromatogr 512:157-163.
8. Goldfarb MF. 1992. Two-dimensional electro-phoretic analysis of immunoglobulin patterns in monoclonal gammopathies. Electrophoresis 13: 440-444.
9. Kaltenbrunner O, Tauer C, Brunner J, Jungbauer A. 1993. Isoprotein analysis by ion-exchange chromatography using a linear pH gradient combined with a salt gradient. J Chromatogr 639:41-49.
10. Tissot JD, Hochstrasser DF, Spertini F, Schifferli JA, Schneider P. 1993. Pattern variations of polyclonal and monoclonal immunoglobulins of different isotypes analyzed by high-resolution two-dimensional electrophoresis. Electrophoresis 14: 227-234.
11. Ackermann M, Marx U, Jager V. 1995. Influence of cell- and Media-derived factors on the integrity of a human monoclonal antibody after secretion into serum-free cell culture supernatants. Biotechnol Bioeng 45:97-106.
12. Takeo K, Suzuno R, Tanaka T, Nakamura K. 1989. Complete separation of anti-hapten antibodies by two-dimensional affinity electrophoresis. Electrophoresis 10:813-818.
13. Takeo K, Tanaka T, Nakamura K, Suzuno R. 1989. Studies on the heterogeneity of anti-hapten antibodies by means of two-dimensional affinity electrophoresis. Electrophoresis 10:818-824.
14. Hamilton G. Robert RBC, Rodkey LS, 1987. Quality control of murine monoclonal antibodies using isoelectric focusing affinity immunoblot analysis. Hybridoma 6:205-217.
15. Jungbauer A, Unterluggauer F, Uhl K, Buchacher A, Steindl F, Pettauer D, Wenisch E. 1988. Scaleup of monoclonal antibody purification using radial streaming ion exchange chromatography. Biotechnol Bioeng 32:326-333.
16. Sticherling M, Schroder JM, Christophers E. 1989. Production and characterization of monoclonal antibodies against the novel neutrophil activating peptide NAP/IL-8. J Immunol 143: 1628-1634.
17. Compton BJ, Gerald JS, Lowe DA, Elander RP. 1989. Micro isoelectric point heterogeneity of a murine monoclonal antibody(L6) originating from cell cultivation conditions. Biotechnol Tech 3:349-354.
18. Grebenau RC, Goldenberg DM, Chang CH, Koch GA, Gold DV, Kunz A, Hansen HJ. 1992. Microheterogeneity of a purified IgGl due to asymmetric Fab glycosylation. Mol Immunol 29:751-758.
19. Nakamura K, Mimura Y, Takeo K. 1993. Immune response to a hapten of fluorescein isothiocyanate in a single mouse analyzed by two-dimensional affinity electrophoresis. Electrophoresis 14:81-87.
20. Nakamura K, Mimura Y, Tanaka T, Fujikura Y, Takeo K. 1993. Affinity maturation of anti-hapten antibodies in a single mouse analyzed by two-dimensional affinity electrophoresis. Electrophoresis 14:1338-1340.
21. Jiskoot W, Beuvery EC, de Koning AA, Herron JN, Crommelin DJ. 1990. Analytical approaches to the tudy of monoclonal antibody stability. Pharm Res 7:1234-1241.
22. Rao P, Williams A, Baldwin-Ferro A, Hanigan E, Kroon D, Makowski M, Meyer E, Numsuwan V, Rubin E, Tran A. 1991. C-Terminal Modification occurs in tissue culture produced OKT. Bio Pharm 4:38-43.
23. Mimura Y, Nakamura K, Takeo K. 1992. Analysis of the interaction between an alpha (1 - 6) dextran-specific mouse hybridoma antibody and dextran B512 by affinity electrophoresis. J Chromatogr 597:345-350.
24. Mimura Y, Rabat EA, Tanaka T, Fujimoto M, Takeo K, Nakamura K. 1995. Microheterogeneity of mouse antidextran monoclonal antibodies. Electrophoresis 16:116-123.
25. Mimura Y, Nakamura K, Tanaka T, Fujimoto M. 1998. Evidence of intra- and extracellular modifications of monoclonal IgG polypeptide chains generating charge heterogeneity. Electrophoresis 19: 767-775.
26. Perkins M, Theiler R, Lunte S, Jeschke M. 2000. Determination of the origin of charge heterogeneity in a murine monoclonal antibody. Pharm Res 17:1110-1117.
27. Janini G, Saptharishi N, Waselus M, Soman G. 2002. Element of a validation method for MU-B3 monoclonal antibody using an imaging capillary isoelectric focusing system. Electrophoresis 23: 1605-1611.
28. Schmelzer AE, Miller WM. 2002. Hyperosmotic stress and elevated pC02 alter monoclonal antibody charge distribution and monosaccharide content. Biotechnol Prog 18:346-353.
29. Moorhouse KG, Nashabeh W, Deveney J, Bjork NS, Mulkerrin MG, Ryskamp T. 1997. Validation of an HPLC method for the analysis of the charge heterogeneity of the recombinant monoclonal antibody IDEC-C2B8 after papain digestion. J Pharm Biomed Anal 16:593-603.
30. Hunt G, Hotaling T, Chen AB. 1998. Validation of a capillary isoelectric focusing method for the recombinant monoclonal antibody C2 B8. J Chromatogr A 800:355-367.
31. Costello MA, Woitttz C, De Feo J, Stremlo D, Wen LL, Palling DJ, Iqbal K, Guzman NA. 1992. Characterization of humanized anti-Tac monoclonal antibody by traditional separation techniques and capillary electrophoresis. J Liq Chromatogr 15:1081-1097.
32. Tsai PK, Bruner MW, Irwin JI, Ip CC, Oliver CN, Nelson RW, Volkin DB, Middaugh CR. 1993. Origin of the isoelectric heterogeneity of monoclonal immunoglobulin hlB. Pharm Res 10:1580-1586.
33. Robinson DK, Chan CP, Yu lp C, Tsai PK, Tung J, Seamans TC, Lenny AB, Lee DK, Irwin J, Silberklang M. 1994. Characterization of a recombinant ntibody produced in the cource of a high yield Fed-batch process. Biotechnol Bioeng 44:727-735.
34. Weitzhandler M, Farnan D, Horvath J, Rohrer JS, Slingsby RW, Avdalovic N, Pohl C. 1998. Protein variant separations by cation-exchange chromatography on tentacle-type polymeric stationary phases. J Chromatogr A 828:365-372.
35. Weitzhandler M, Farnan D, Rohrer JS, Avdalovic N. 2001. Protein variant separations using cation exchange chromatography on grafted, polymeric stationary phases. Proteomics 1:179-185.
36. Santora LC, Krull IS, Grant K. 1999. Characterization of recombinant human monoclonal tissue necrosis factor-alpha antibody using cationexchange HPLC and capillary isoelectric focusing. Anal Biochem 275:98-108.
37. Santora LC, Kaymakcalan Z, Sakorafas P, Krull IS, Grant K. 2001. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem 299:119-129.
38. Santora LC, Stanley K, Krull IS, Grant K. 2006. Characterization of maleuric acid derivatives on transgenic human monoclonal antibody due to post-secretional modifications in goat milk. Biomed Chromatogr 20:843-856.
39. Hunt G, Moorhouse KG, Chen AB. 1996. Capillary isoelectric focusing and sodium dodecyl sulfate-capillary gel electrophoresis of recombinant humanized monoclonal antibody H ER2. J Chromatogr A 744:295-301.
40. Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB. 2001. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl 752: 233-245.
41. Zhang W, Czupryn MJ. 2003. Analysis of isoaspartate in a recombinant monoclonal antibody and its charge isoforms. J Pharm Biomed Anal 30: 1479-1490.
42. Dillon TM, Bondarenko PV, Rehder DS, Pipes GD, Kleemann GR, Ricci MS. 2006. Optimization of a reversed-phase high-performance liquid chroma-tography/mass spectrometry method for characterizing recombinant antibody heterogeneity and stability. J Chromatogr A 1120:112-120. (Epub 2006 Jan 2030.)
43. Dillon TM, Bondarenko PV, Speed Ricci M. 2004. Development of an analytical reversed-phase high-performance liquid chromatography-electro-spray ionization mass spectrometry method for characterization of recombinant antibodies. J Chromatogr A 1053:299-305.
44. Huang L, Lu J, Wroblewski VJ, Beals JM, Riggin RM. 2005. In vivo deamidation characterization of onoclonal antibody by LC/MS/MS. Anal Chem 77:1432-1439.
45. Zhu L, van de Lavoir MC, Albanese J, Beenhouwer DO, Cardarelli PM, Cuison S, Deng DF, Deshpande S, Diamond JH, Green L, Halk EL, Heyer BS, Kay RM, Kerchner A, Leighton PA, Mather CM, Morrison SL, Nikolov ZL, Passmore DB, Pradas-Monne A, Preston BT, Rangan VS, Shi M, Srinivasan M, White SG, Winters-Digiacinto P, Wong S, Zhou W, Etches RJ. 2005. Production of human monoclonal antibody in eggs of chimeric chickens. Nat Biotechnol 23:1159-1169. (Epub 2005 Aug 1128.)
46. Beck A, Bussat MC, Zorn N, Robillard V, Klinguer-Hamour C, Chenu S, Goetsch L, Corvaia N, Van Dorsselaer A, Haeuw JF. 2005. Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NSO cells. J Chromatogr B Analyt Technol Biomed Life Sci 819:203-218.
47. Lyubarskaya Y, Houde D, Woodard J, Murphy D, Mhatre R. 2006. Analysis of recombinant monoclonal antibody isoforms by electrospray ionization mass spectrometry as a strategy for streamlining characterization of recombinant monoclonal antibody charge heterogeneity. Anal Biochem 348:24-39 (Epub 2005 Oct 2025.)
48. Johnson KA, Paisley-Flango K, Tangarone BS, Porter TJ, Rouse JC. 2007. Cation exchange-HPLC and mass spectrometry reveal C-terminal amidation of an IgGl heavy chain. Anal Biochem 360:75-83 (Epub 2006 Oct 2030.)
49. Notani GW, Munro AJ, Knopf PM. 1966. A charge difference between an intracellular and secreted mouse myeloma globulin. Biochem Biophys Res Commun 25:395-401.
50. Wenisch E, Reiter S, Hinger S, Steindl F, Tauer C, Jungbauer A, Katinger H, Righetti PG. 1990. Shifts of isoelectric points between cellular and secreted antibodies as revealed by isoelectric focusing and immobilized pH gradients. Electrophoresis 11:966-969.
51. Kroon DJ, Baldwin-Ferro A, Lalan P. 1992. Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping. Pharm Res 9:1386-1393.
52. Chelius D, Rehder DS, Bondarenko PV. 2005. Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies. Anal Chem 77:6004-6011.
53. Usami A, Ohtsu A, Takahama S, Fujii T. 1996. The effect of pH, hydrogen peroxide and temperature on the stability of human monoclonal antibody. J Pharm Biomed Anal 14:1133-1140.
54. Dai HJ, Krull IS. 1998. Thermal stability studies of immunoglobulins using capillary isoelectric ocusing and capillary zone electrophoretic methods. J Chromatogr A 807:121-128.
55. Alexander AJ, Hughes DE. 1995. Monitoring of IgG antibody thermal stability by micellar electro-kinetic capillary chromatography and matrix-assisted laser desorption/ionization mass spectrometry. Anal Chem 67:3626-3632.
56. Andya JD, Maa YF, Costantino HR, Nguyen PA, Dasovich N, Sweeney TD, Hsu CC, Shire SJ. 1999. The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody. Pharm Res 16:350-358.
57. Rao PE, Kroon DJ. 1993. Orthoclone OKT3. Chemical mechanisms and functional effects of degradation of a therapeutic monoclonal antibody. In: Wang YJ, Pearlman R, editors. Stability and characterization of protein and peptide drugs: Case histories. New York: Plenum Press. 135-158.
58. Wenisch E, Jungbauer A, Tauer C, Reiter M, Gruber G, Steindl F, Katinger H. 1989. Isolation of human monoclonal antibody isoproteins by preparative isoelectric focusing in immobilized pH gradients. J Biochem Biophys Methods 18:309-322.
59. Bai L, Burman S, Gledhill L. 2000. Development of ion exchange chromatography methods for monoclonal antibodies. J Pharm Biomed Anal 22:605-611.
60. Cacia J, Keck R, Presta LG, Frenz J. 1996. Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: Identification and effect on binding affinity. Biochemistry 35:1897-1903.
61. Harris RJ. 2005. Heterogeneity of recombinant antibodies: Linking structure to function. Dev Biol (Basel) 122:117-127.
62. Rehder DS, Dillon TM, Pipes GD, Bondarenko PV. 2006. Reversed-phase liquid chromatography/ mass spectrometry analysis of reduced monoclonal antibodies in pharmaceutics. J Chromatogr A 1102:164-175. (Epub 2005 Nov 2017.)
63. Gadgil HS, Bondarenko PV, Pipes GD, Dillon TM, Banks D, Abel J, Kleemann GR, Treuheit MJ. 2006. Identification of cysteinylation of a free cysteine in the Fab region of a recombinant monoclonal IgGl antibody using Lys-C limited proteolysis coupled with LC/MS analysis. Anal Biochem 355:165-174. (Epub 2006 Jun 2015.)
64. Tous GI, Wei Z, Feng J, Bilbulian S, Bowen S, Smith J, Strouse R, McGeehan P, Casas-Finet J, Schenerman MA. 2005. Characterization of a novel modification to monoclonal antibodies: Thioether cross-link of heavy and light chains. Anal Chem 77:2675-2682.
65. Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, Pedley B, Adair JR. 1993. A single mino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol 30:105-108.
66. Brody T. 1997. Multistep denaturation and hierarchy of disulfide bond cleavage of a monoclonal antibody. Anal Biochem 247:247-256.
67. Schuurman J, Perdok GJ, Gorter AD, Aalberse RC. 2001. The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol Immunol 38:1-8.
68. Hunt G, Nashabeh W. 1999. Capillary electrophoresis sodium dodecyl sulfate nongel sieving analysis of a therapeutic recombinant monoclonal antibody: A biotechnology perspective. Anal Chem 71:2390-2397.
69. Schauenstein E, Schauenstein K, Dachs F, Reiter M, Leitsberger A, Weblacher M, Maninger K, Horejsi H, Steinschifter W, Hirschmann C, Felsner P. 1996. Reactive disulfide bonds in immunoglobulin G. A unique feature in serum proteins of different species. Biochem Mol Biol Int 40:433-446.
70. Zhang W, Czupryn MJ. 2002. Free sulfhydryl in recombinant monoclonal antibodies. Biotechnol Prog 18:509-513.
71. Taylor FR, Prentice HL, Garber EA, Fajardo HA, Vasilyeva E, Blake Pepinsky R. 2006. Suppression of sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample preparation artifacts for analysis of IgG4 half-antibody. Anal Biochem 353:204-208. (Epub 2006 Mar 2009.)
72. Chaderjian WB, Chin ET, Harris RJ, Etcheverry TM. 2005. Effect of copper sulfate on performance of a serum-free CHO cell culture process and the level of free thiol in the recombinant antibody expressed. Biotechnol Prog 21:550-553.
73. Sears DW, Mohrer J, Beychok S. 1977. Relative susceptibilities of the interchain disulfides of an immunoglobulin G molecule to reduction by dithiothreitol. Biochemistry 16:2031-2035.
74. Virella G, Parkhouse RM. 1973. Sensitivity to reduction of human immunoglobulin G of different heavy chain sub-classes. Immunochemistry 10: 213-217.
75. Nashef AS, Osuga DT, Lee HS, Ahmed AI, Whitaker JR, Feeney RE. 1977. Effects of alkali on proteins. Disulfides and their products. J Agric Food Chem 25:245-251.
76. Florence TM. 1980. Degradation of protein disulphide bonds in dilute alkali. Biochem J 189:507-520.
77. Galande AK, Trent JO, Spatola AF. 2003. Understanding base-assisted desulfurization using a variety of disulfide-bridged peptides. Biopolymers 71:534-551.
78. asilyeva E, Woodard J, Taylor FR, Kretschmer , Fajardo H, Lyubarskaya Y, Kobayashi K, Ding ey A, Mhatre R. 2004. Development of a chipased capillary gel electrophoresis method for uantification of a half-antibody in immunoglobulin G4 samples. Electrophoresis 25:3890-3896.
79. Forrer K, Hammer S, Helk B. 2004. Chip-based gel electrophoresis method for the quantification of half-antibody species in IgG4 and their by- and degradation products. Anal Biochem 334:81-88.
80. Abel CA, Spiegelberg HL, Grey HM. 1968. The carbohydrate contents of fragments and polypeptide chains of human gamma-G-myeloma proteins of different heavy-chain subclasses. Biochemistry 7:1271-1278.
81. Mizuochi T, Taniguchi T, Shimizu A, Kobata A. 1982. Structural and numerical variations of the carbohydrate moiety of immunoglobulin G. J Immunol 129:2016-2020.
82. Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, Rademacher TW, Mizuochi T, Taniguchi T, Matsuta K, Takeuchi F, Nasano Y, Miyamoto T, Kobata A. 1985. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316:452-457.
83. Taniguchi T, Mizuochi T, Beale M, Dwek RA, Rademacher TW, Kobata A. 1985. Structures of the sugar chains of rabbit immunoglobulin G: Occurrence of asparagine-linked sugar chains in Fab fragment. Biochemistry 24:5551-5557.
84. Mizuochi T, Hamako J, Titani K. 1987. Structures of the sugar chains of mouse immunoglobulin G. Arch Biochem Biophys 257:387-394.
85. Jefferis R. 2005. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 21:11-16.
86. Co MS, Scheinberg DA, Avdalovic NM, McGraw K, Vasquez M, Caron PC, Queen C. 1993. Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody. Mol Immunol 30:1361-1367.
87. Leibiger H, Wustner D, Stigler RD, Marx U. 1999. Variable domain-linked oligosaccharides of a human monoclonal IgG: Structure and influence on antigen binding. Biochem J 338:529-538.
88. Fanger MW, Smyth DG. 1972. The oligosaccharide units of rabbit immunoglobulin G. Multiple carbohydrate attachment sites. Biochem J 127: 757-765.
89. Fanger MW, Smyth DG. 1972. The oligosaccharide units of rabbit immunoglobulin G. Asymmetric attachment of C2-oligosaccharide. Biochem J 127:767-774.
90. Sawidou G, Klein M, Home C, Hofmann T, Dorrington KJ. 1981. A monoclonal immunoglobulin Gl in which some molecules possess glycosylated light chains-I. Site of glycosylation. Mol Immunol 18:793-805.
91. Middaugh CR, Litman GW. 1987. Atypical glyco ylation of an IgG monoclonal cryoimmunoglobu in. J Biol Chem 262:3671-3673.
92. Wallick SC, Rabat EA, Morrison SL. 1988. Glycosylation of a VH residue of a monoclonal antibody against alpha (1 - 6) dextran increases its affinity for antigen. J Exp Med 168:1099-1109.
93. Rothman RJ, Warren L, Vliegenthart JF, Hard KJ. 1989. Clonal analysis of the glycosylation of immunoglobulin G secreted by murine hybrido-mas. Biochemistry 28:1377-1384.
94. Malan Borel I, Gentile T, Angelucci J, Margni RA, Binaghi RA. 1990. Asymmetric Fab glycosylation in guinea-pig IgGl and Ig G2. Immunology 70: 281-283.
95. Bond A, Cooke A, Hay FC. 1990. Glycosylation of IgG, immune complexes and IgG subclasses in the MRL-lpr/lpr mouse model of rheumatoid arthritis. Eur J Immunol 20:2229-2233.
96. Wright A, Tao MH, Rabat EA, Morrison SL. 1991. Antibody variable region glycosylation: Position effects on antigen binding and carbohydrate structure. EMBO J 10:2717-2723.
97. Coco-Martin JM, Brunink F, van der Velden-de Groot TA, Beuvery EC. 1992. Analysis of glycoforms present in two mouse IgG2a monoclonal antibody preparations. J Immunol Methods 155: 241-248.
98. Couto JR, Padlan EA, Blank EW, Peterson JA, Ceriani RL. 1994. Humanization of RC4G3, an anti-human carcinoma antibody. Hybridoma 13: 215-219.
99. Leung SO, Dion AS, Pellegrini MC, Losman MJ, Grebenau RC, Goldenberg DM, Hansen HJ. 1995. Effect of VR framework-1 glycosylation on the binding affinity of lymphoma-specific murine and chimeric LL2 antibodies and its potential use as a novel conjugation site. Int J Cancer 60: 534-538.
100. Leung SO, Goldenberg DM, Dion AS, Pellegrini MC, Shevitz J, Shih LB, Hansen HJ. 1995. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/ lymphoma antibody, LL2. Mol Immunol 32: 1413-1427.
101. Mechref Y, Muzikar J, Novotny MV. 2005. Comprehensive assessment of N-glycans derived from a murine monoclonal antibody: A case for multimethodological approach. Electrophoresis 26:2034-2046.
102. Huang L, Biolsi S, Bales RR, Ruchibhotla U. 2006. Impact of variable domain glycosylation on antibody clearance: An LC/MS characterization. Anal Biochem 349:197-207. (Epub 2005 Nov 2028.)
103. Endo T, Wright A, Morrison SL, Robata A. 1995. Glycosylation of the variable region of immunoglobulin G - site specific maturation of the sugar chains. Mol Immunol 32:931-940.
104. Coloma MJ, Trinh RR, Martinez AR, Morrison SL. 1999. Position effects of variable region carbohydrate on the affinity and in vivo behavior of an nti-(l → 6) dextran antibody. J Immunol 162: 2162-2170.
105. Parham P. 1983. On the fragmentation of monoclonal IgGl, IgG2a, and IgG2b from BALB/c mice. J Immunol 131:2895-2902.
106. Burton DR. 1985. Immunoglobulin G: Functional sites. Mol Immunol 22:161-206.
107. Rim H, Yamaguchi Y, Masuda R, Matsunaga C, Yamamoto R, Irimura T, Takahashi N, Rato R, Arata Y. 1994. O-glycosylation in hinge region of mouse immunoglobulin G2b. J Biol Chem 269: 12345-12350.
108. Hagmann ML, Rionka C, Schreiner M, Schwer C. 1998. Characterization of the F(ab')2 fragment of a murine monoclonal antibody using capillary isoelectric focusing and electrospray ionization mass spectrometry. J Chromatogr A 816:49-58.
109. Hirayama R, Yuji R, Yamada N, Rato R, Arata Y, Shimada I. 1998. Complete and rapid peptide and glycopeptide mapping of mouse monoclonal antibody by LC/MS/MS using ion trap mass spectrometry. Anal Chem 70:2718-2725.
110. Jiskoot W, van de Werken G, Martin JM, Green BN, Beuvery EC, Crommelin DJ. 1992. Application of electrospray mass spectrometry (ES-MS) for the analysis of monoclonal antibody Fc subunits. Pharm Res 9:945-951.
111. Kamoda S, Ishikawa R, Rakehi R. 2006. Capillary electrophoresis with laser-induced fluorescence detection for detailed studies on N-linked oligosaccharide profile of therapeutic recombinant monoclonal antibodies. J Chromatogr A 1133: 332-339. (Epub 2006 Sep 2001.)
112. Santora LC, Krull IS, Grant K. 2002. Determination of recombinant monoclonal antibodies and noncovalent antigen TNF-a trimer using Q-TOF mass spectrometry. Spectroscopy 17:50-57.
113. Lewis DA, Guzzetta AW, Hancock WS, Costello M. 1994. Characterization of humanized anti-TAC, an antibody directed against the interleukin 2 receptor, using electrospray ionization mass spectrometry by direct infusion, LC/MS, and MS/MS. Anal Chem 66:585-595.
114. Roberts GD, Johnson WP, Burman S, Anumula RR, Carr SA. 1995. An integrated strategy for structural characterization of the protein and carbohydrate components of monoclonal antibodies: Application to anti-respiratory syncytial virus MAb. Anal Chem 67:3613-3625.
115. Ashton DS, Beddell CR, Cooper DJ, Craig SJ, Lines AC, Oliver RW, Smith MA. 1995. Mass spectrometry of the humanized monoclonal antibody CAMPATH 1H. Anal Chem 67:835-842.
116. Lines AC. 1996. High-performance liquid chromatographic mapping of the oligosaccharides released from the humanised immunoglobulin, CAMPATH 1H. J Pharm Biomed Anal 14:601-608.
117. Routier FH, Davies MJ, Bergemann K, Hounsell EF. 1997. The glycosylation pattern of humanized IgGI antibody (D1.3) expressed in CHO cells. Glycoconj J 14:201-207.
118. Ma S, Nashabeh W. 1999. Carbohydrate analysis of a chimeric recombinant monoclonal antibody by capillary electrophoresis with laser-induced fluorescence detection. Anal Chem 71:5185-5192.
119. Matamoros Fernandez LE, Kalume DE, Calvo L, Fernandez Mallo M, Vallin A, Roepstorff P. 2001. Characterization of a recombinant monoclonal antibody by mass spectrometry combined with liquid chromatography. J Chromatogr B Biomed Sci Appl 752:247-261.
120. Kemminer SE, Conradt HS, Nimtz M, Sagi D, Peter-Katalinic J, Diekmann O, Drmic I, Muthing J. 2001. Production and molecular characterization of clinical phase i anti-melanoma mouse IgG3 monoclonal antibody R24. Biotechnol Prog 17: 809-821.
121. Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M. 2001. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng 74:288-294.
122. Wang L, Amphlett G, Lambert JM, Blattler W, Zhang W. 2005. Structural characterization of a recombinant monoclonal antibody by electrospray time-of-flight mass spectrometry. Pharm Res 22: 1338-1349 (Epub 2005 Aug 1333.)
123. Wang F, Nakouzi A, Alvarez M, Zaragoza O, Angeletti RH, Casadevall A. 2006. Structural and functional characterization of glycosylation in an immunoglobulin Gl to Cryptococcus neoformans glucuronoxylomannan. Mol Immunol 43:987-998. (Epub 2005 Jul 2019.)
124. Siemiatkoski J, Lyubarskaya Y, Houde D, Tep S, Mhatre R. 2006. A comparison of three techniques for quantitative carbohydrate analysis used in characterization of therapeutic antibodies. Carbohydr Res 341:410-419. (Epub 2005 Dec 2027.)
125. Kroon DJ, Freedy J, Burinsky DJ, Sharma B. 1995. Rapid profiling of carbohydrate glycoforms in monoclonal antibodies using MALDI/TOF mass spectrometry. J Pharm Biomed Anal 13:1049-1054.
126. Sunday BR. 2003. Structure characterization of a recombinant monoclonal antibody with one- and two-dimensional high performance liquid chromatography with on-line electrospray ionization mass spectrometry. Bioprocessing J May/June: 37-43.
127. Wan HZ, Kaneshiro S, Frenz J, Cacia J. 2001. Rapid method for monitoring galactosylation levels during recombinant antibody production y electrospray mass spectrometry with selective-ion monitoring. J Chromatogr A 913:437-446.
128. Tandai M, Endo T, Sasaki S, Masuho Y, Kochibe N, Kobata A. 1991. Structural study of the sugar moieties of monoclonal antibodies secreted by human-mouse hybridoma. Arch Biochem Biophys 291:339-348.
129. Ip CC, Miller WJ, Silberklang M, Mark GE, Ellis RW, Huang L, Glushka J, Van Halbeek H, Zhu J, Alhadeff JA. 1994. Structural characterization of the N-glycans of a humanized anti-CD 18 murine immunoglobulin G. Arch Biochem Biophys 308: 387-399.
130. Hills AE, Patel A, Boyd P, James DC. 2001. Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells. Biotechnol Bioeng 75:239-251.
131. Bailey MJ, Hooker AD, Adams CS, Zhang S, James DC. 2005. A platform for high-throughput molecular characterization of recombinant monoclonal antibodies. J Chromatogr B Analyt Technol Biomed Life Sci 826:177-187. (Epub 2005 Sep 2019.)
132. Krotkiewski H, Gronberg G, Krotkiewska B, Nilsson B, Svensson S. 1990. The carbohydrate structures of a mouse monoclonal IgG antibody O KT3. J Biol Chem 265:20195-20201.
133. Bihoreau N, Ramon C, Lazard M, Schmitter JM. 1997. Combination of capillary electrophoresis and matrix-assisted laser desorption ionization mass spectrometry for glycosylation analysis of a human monoclonal anti-Rhesus(D) antibody. J Chromatogr B Biomed Sci Appl 697:123-133.
134. Kunkel JP, Jan DC, Jamieson JC, Butler M. 1998. Dissolved oxygen concentration in serum-free continuous culture affects N-linked glycosylation of a monoclonal antibody. J Biotechnol 62:55-71.
135. Muthing J, Kemminer SE, Conradt HS, Sagi D, Nimtz M, Karst U, Peter-Katalinic J. 2003. Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I antimelanoma mouse IgG3 monoclonal antibody R24. Biotechnol Bioeng 83:321-334.
136. Raju TS, Scallon BJ. 2006. Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain. Biochem Biophys Res Commun 341:797-803. (Epub 2006 Jan 2019.)
137. Lund J, Takahashi N, Nakagawa H, Goodall M, Bentley T, Hindley SA, Tyler R, Jefferis R. 1993. Control of IgG/Fc glycosylation: A comparison of oligosaccharides from chimeric human/mouse and mouse subclass immunoglobulin Gs. Mol Immunol 30:741-748.
138. Sheeley DM, Merrill BM, Taylor LC. 1997. Characterization of monoclonal antibody glycosylation: Comparison of expression systems and identification of terminal alpha-linked galactose. Anal Biochem 247:102-110.
139. Patel TP, Parekh RB, Moellering BJ, Prior CP. 1992. Different culture methods lead to differences in glycosylation of a murine IgG monoclonal antibody. Biochem J 285:839-845.
140. Kumpel BM, Rademacher TW, Rook GA, Williams PJ, Wilson IB. 1994. Galactosylation of human IgG monoclonal anti-D produced by EBV-trans-formed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity. Hum Antibodies Hybridomas 5:143-151.
141. Lifely MR, Hale C, Boyce S, Keen MJ, Phillips J. 1995. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 5:813-822.
142. Kunkel JP, Jan DC, Butler M, Jamieson JC. 2000. Comparisons of the glycosylation of a monoclonal antibody produced under nominally identical cell culture conditions in two different bioreactors. Biotechnol Prog 16:462-470.
143. Serrato JA, Palomares LA, Meneses-Acosta A, Ramirez OT. 2004. Heterogeneous conditions in dissolved oxygen affect N-glycosylation but not productivity of a monoclonal antibody in hybridoma cultures. Biotechnol Bioeng 88:176-188.
144. Hamako J, Matsui T, Ozeki Y, Mizuochi T, Titani K. 1993. Comparative studies of asparagine-linked sugar chains of immunoglobulin G from eleven mammalian species. Comp Biochem Physiol B 106:949-954.
145. Raju TS, Briggs JB, Borge SM, Jones AJ. 2000. Species-specific variation in glycosylation of IgG: Evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 10:477-486.
146. Borrebaeck CK, Malmborg AC, Ohlin M. 1993. Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics? Immunol Today 14:477-479.
147. Jefferis R, Lund J. 1997. Glycosylation of antibody molecules: Structural and functional significance. Chem Immunol 65:111-128.
148. Jefferis R, Lund J, Pound JD. 1998. IgG-Fc-mediated effector functions: Molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol Rev 163:59-76.
149. Matsuda F, Ishii K, Bourvagnet P, Kuma K, Hayashida H, Miyata T, Honjo T. 1998. The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus. J Exp Med 188:2151-2162.
150. Kawasaki K, Minoshima S, Nakato E, Shibuya K, Shintani A, Schmeits JL, Wang J, Shimizu N. 1997. One-megabase sequence analysis of the human immunoglobulin lambda gene locus. Genome Res 7:250-261.
151. Schable KF, Zachau HG. 1993. The variable genes of the human immunoglobulin kappa locus. Biol Chem Hoppe Seyler 374:1001-1022.
152. Brensing-Kuppers J, Zocher I, Thiebe R, Zachau HG. 1997. The human immunoglobulin kappa locus on yeast artificial chromosomes (YACs). Gene 191:173-181.
153. Kawasaki K, Minoshima S, Nakato E, Shibuya K, Shintani A, Asakawa S, Sasaki T, Klobeck HG, Combriato G, Zachau HG, Shimizu N. 2001. Evolutionary dynamics of the human immunoglobulin kappa locus and the germline repertoire of the Vkappa genes. Eur J Immunol 31:1017-1028.
154. Kaplan AP, Hood LE, Terry WD, Metzger H. 1971. Amino terminal sequences of human immunoglobulin heavy chains. Immunochemistry 8: 801-811.
155. Stoppini M, Bellotti V, Negri A, Merlini G, Garver F, Ferri G. 1995. Characterization of the two unique human anti-flavin monoclonal immunoglobulins. Eur J Biochem 228:886-893.
156. Akashi S, Kato K, Torizawa T, Dohmae N, Yamaguchi H, Kamachi M, Harada A, Imanaka T, Shimada I, Takio K. 1997. Structural characterization of mouse monoclonal antibody 13-l against a porphyrin derivative: Identification of a disulfide bond in CDR-H3 of Mabl3-1. Biochem Biophys Res Commun 240:566-572.
157. Dick LW Jr, Kim C, Qiu D, Cheng KC. 2007. Determination of the origin of
158. Liu H, Gaza-Bulseco G, Sun J. 2006. Characterization of the stability of a fully human monoclonal IgG after prolonged incubation at elevated temperature. J Chromatogr B Analyt Technol Biomed Life Sci 837:35-43. (Epub 2006 Apr 2027.)
159. Yu L, Vizel A, Huff MB, Young M, Remmele RL Jr, He B. 2006. Investigation of N-terminal glutamate cyclization of recombinant monoclonal antibody in formulation development. J Pharm Biomed Anal 42:455-463. (Epub 2006 Jul 2007.)
160. Chelius D, Jing K, Lueras A, Rehder DS, Dillon TM, Vizel A, Rajan RS, Li T, Treuheit MJ, Bondarenko PV. 2006. Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies. Anal Chem 78:2370-2376.
161. Ellison JW, Berson BJ, Hood LE. 1982. The nucleotide sequence of a human immunoglobulin C gammal gene. Nucleic Acids Res 10:4071-4079.
162. Harris RJ, Wagner KL, Spellman MW. 1990. Structural characterization of a recombinant CD4-IgG hybrid molecule. Eur J Biochem 194: 611-620.
163. Harris RJ, Murnane AA, Utter SL, Wagner KL, Cox ET, Polastri GD, Helder JC, Sliwkowski MB. 1993. Assessing genetic heterogeneity in production cell lines: Detection by peptide mapping of a ow level Tyr to Gln sequence variant in a recombinant antibody. Bio/technology 11:1293-1297.
164. Lazar AC, Kloczewiak MA, Mazsaroff I. 2004. Matrix-assisted laser desorption/ionization mass spectrometry for the evaluation of the C-terminal lysine distribution of a recombinant monoclonal antibody. Rapid Commun Mass Spectrom 18:239-244.
165. Harris RJ. 1995. Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture. J Chromatogr A 705: 129-134.
166. Wakankar AA, Borchardt RT, Eigenbrot C, Shia S, Wang YJ, Shire SJ, Liu JL. 2007. Aspartate isomerization in the complementarity-determining regions of two closely related monoclonal antibodies. Biochemistry 46:1534-1544. (Epub 2007 Jan 1517.)
167. Wright HT. 1991. Nonenzymatic deamidation of asparaginyl and glutaminyl residues in proteins. Crit Rev Biochem Mol Biol 26:1-52.
168. Manning MC, Patel K, Borchardt RT. 1989. Stability of protein pharmaceuticals. Pharm Res 6:903-918.
169. Geiger T, Clarke S. 1987. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem 262:785-794.
170. Kwong MY, Harris RJ. 1994. Identification of succinimide sites in proteins by N-terminal sequence analysis after alkaline hydroxylamine cleavage. Protein Sci 3:147-149.
171. Stephenson RC, Clarke S. 1989. Succinimide formation from aspartyl and asparaginyl peptides as a model for the spontaneous degradation of proteins. J Biol Chem 264:6164-6170.
172. Robinson NE, Robinson AB. 2001. Molecular clocks. Proc Natl Acad Sci USA 98:944-949.
173. Clarke S. 1987. Propensity for spontaneous succinimide formation from aspartyl and asparaginyl residues in cellular proteins. Int J Pept Protein Res 30:808-821.
174. Xie M, Schowen RL. 1999. Secondary structure and protein deamidation. J Pharm Sci 88: 8-13.
175. Patel K, Borchardt RT. 1990. Chemical pathways of peptide degradation. II. Kinetics of deamidation of an asparaginyl residue in a model hexapeptide. Pharm Res 7:703-711.
176. Song Y, Schowen RL, Borchardt RT, Topp EM. 2001. Effect of 'pH' on the rate of asparagine deamidation in polymeric formulations: 'pH'-rate profile. J Pharm Sci 90:141-156.
177. Stratton LP, Kelly RM, Rowe J, Shively JE, Smith DD, Carpenter JF, Manning MC. 2001. Controlling deamidation rates in a model peptide: Effects f temperature, peptide concentration, and additives. J Pharm Sci 90:2141-2148.
178. Robinson AB, Scotchler JW, McKerrow JH. 1973. Rates of nonenzymatic deamidation of glutaminyl and asparaginyl residues in pentapeptides. J Am Chem Soc 95:8156-8159.
179. Wakankar AA, Liu J, Vandervelde D, Wang YJ, Shire SJ, Borchardt RT. 2007. The effect of cosolutes on the isomerization of aspartic acid residues and conformational stability in a monoclonal antibody. J Pharm Sci 96:1708-1718.
180. Deisenhofer J. 1981. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Sta-phylococcus aureus at 2.9-and 2.8-A resolution. Biochemistry 20:2361-2370.
181. Thies MJ, Mayer J, Augustine JG, Frederick CA, Lilie H, Buchner J. 1999. Folding and association of the antibody domain C H3: Prolyl isomerization preceeds dimerization. J Mol Biol 293:67-79.
182. Lilie H, Rudolph R, Buchner J. 1995. Association of antibody chains at different stages of folding: Prolyl isomerization occurs after formation of quaternary structure. J Mol Biol 248:190-201.
183. Shen JF, Kwong YM, Keck GR, Harris JR. 1996. The application of tert-Butylhydroperoxide oxidization to study sites of potential methionine oxidization in a recombinant antibody. Tech Protein Chem VII VII:275-284.
184. Lam XM, Yang JY, Cleland JL. 1997. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody H ER2. J Pharm Sci 86:1250-1255.
185. Chumsae C, Gaza-Bulseco G, Sun J, Liu H. 2007. Comparison of methionine oxidation in thermal stability and chemically stressed samples of a fully human monoclonal antibody. J Chromatogr B Analyt Technol Biomed Life Sci 850:285-294.
186. Wei Z, Feng J, Lin HY, Mullapudi S, Bishop E, Tous GI, Casas-Finet J, Hakki F, Strouse R, Schenerman MA. 2007. Identification of a single tryptophan residue as critical for binding activity in a humanized monoclonal antibody against respiratory syncytial virus. Anal Chem 79:2797-2805. (Epub 2007 Feb 2724.)
187. Yang J, Wang S, Liu J, Raghani A. 2007. Determination of tryptophan oxidation of monoclonal antibody by reversed phase high performance liquid chromatography. J Chromatogr A 1156: 174-182. (Epub 2007 Feb 2015.)
188. Kaneshige H. 1987. Nonenzymatic glycosylation of serum IgG and its effect on antibody activity in patients with diabetes mellitus. Diabetes 36:822-828.
189. Dolhofer R, Siess EA, Wieland OH. 1985. Nonenzymatic glycation of immunoglobulins leads to an mpairment of immunoreactivity. Biol Chem Hoppe Seyler 366:361-366.
190. Danze PM, Tarjoman A, Rousseaux J, Fossati P, Dautrevaux M. 1987. Evidence for an increased glycation of IgG in diabetic patients. Clin Chim Acta 166:143-153.
191. Hammes HP, Kiefel V, Laube H, Federlin K. 1990. Impaired agglutination of IgM resulting from non-enzymatic glycation in diabetes mellitus. Diabetes Res Clin Pract 9:37-42.
192. Lapolla A, Fedele D, Aronica R, Garbeglio M, D'Alpaos M, Seraglia R, Traldi P. 1997. Evaluation of IgG glycation levels by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom 11:1342-1346.
193. Lapolla A, Fedele D, Garbeglio M, Martano L, Tonani R, Seraglia R, Favretto D, Fedrigo MA, Traldi P. 2000. Matrix-assisted laser desorption/ ionization mass spectrometry, enzymatic digestion, and molecular modeling in the study of nonenzymatic glycation of IgG. J Am Soc Mass Spectrom 11:153-159.
194. Dolhofer-Bliesener R, Gerbitz KD. 1990. Impairment by glycation of immunoglobulin G Fc fragment function. Scand J Clin Lab Invest 50:739-746.
195. Hennessey PJ, Black CT, Andrassy RJ. 1991. Nonenzymatic glycosylation of immunoglobulin G impairs complement fixation. JPEN J Parenter Enteral Nutr 15:60-64.
196. Morin LG, Austin GE, Burkhalter A. 1987. Nonenzymatic glycation of immunoglobulins does not impair antigen-antibody binding. Clin Chem 33: 692-694.
197. Morin LG, Austin GE, Rodey GE, Johnson JE. 1989. Nonenzymic glycation of human immunoglobulins does not impair their immunoreactivity. Clin Chem 35:1039-1042.
198. Menini T, Gugliucci A, Stahl AJ. 1992. Polyclonal immunoglobulin M: Location of glycation sites. Clin Chim Acta 213:23-35.
199. Dolhofer-Bliesener R, Gerbitz KD. 1990. Effect of nonenzymatic glycation on the structure of immunoglobulin G. Biol Chem Hoppe Seyler 371:693-697.
200. Sasaki Y, Mori T, Shiiki H, Dohi K, Ishikawa H. 1993. Non-enzymatic glycosylation of mouse monoclonal antibody reduces its binding activity to antigen. Clin Chim Acta 220:119-121.
201. Kennedy DM, Skillen AW, Self CH. 1994. Glycation of monoclonal antibodies impairs their ability to bind antigen. Clin Exp Immunol 98:245-251.
202. Vrdoljak A, Trescec A, Benko B, Hecimovic D, Simic M. 2004. In vitro glycation of human immunoglobulin G. Clin Chim Acta 345:105-111.
203. Jairajpuri DS, Fatima S, Saleemuddin M. 2007. Immunoglobulin glycation with fructose: A comparative study. Clin Chim Acta 378:86-92. (Epub 2006 Nov 2006.)
204. Connell GE, Painter RH. 1966. Fragmentation of immunoglobulin during storage. Can J Biochem 44:371-379.
205. Smith AM, Dowd AJ, Heffernan M, Robertson CD, Dalton JP. 1993. Fasciola hepatica: A secreted cathepsin L-like proteinase cleaves host immunoglobulin. Int J Parasitol 23:977-983.
206. Kong Y, Chung YB, Cho SY, Kang SY. 1994. Cleavage of immunoglobulin G by excretory-secretory cathepsin S-like protease of Spirometra mansoni plerocercoid. Parasitology 109:611-621.
207. Berasain P, Carmona C, Frangione B, Dalton JP, Goni F. 2000. Fasciola hepatica: Parasite-secreted proteinases degrade all human IgG subclasses: Determination of the specific cleavage sites and identification of the immunoglobulin fragments produced. Exp Parasitol 99-110.
208. Gearing AJ, Thorpe SJ, Miller K, Mangan M, Varley PG, Dudgeon T, Ward G, Turner C, Thorpe R. 2002. Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin. Immunol Lett 81:41-48.
209. Turner MW, Bennich H. 1968. Subfragments from the Fc fragment of human immunoglobulin G. Isolation and physicochemical charaterization. Biochem J 107:171-178.
210. Matthews N, Stewart G, Stanworth DR. 1971. Characterisation of a new tryptic sub-fragment of human and rabbit IgG Fc fragment. Immuno-chemistry 8:973-981.
211. Connell GE, Porter RR. 1971. A new enzymic fragment (Facb) of rabbit immunoglobulin G. Biochem J 124:53.
212. Natvig JB, Turner MW. 1971. Localization of Gm markers to different molecular regions of the Fc fragment. Clin Exp Immunol 8:685-700.
213. Ellerson JR, Yasmeen D, Painter RH, Dorrington KJ. 1972. A fragment corresponding to the C(H)2 region of immunoglobulin G (IgG) with complement fixing activity. FEBS Lett 24:318-322.
214. Ellerson JR, Yasmeen D, Painter RH, Dorrington KJ. 1976. Structure and function of immunoglobulin domains. III. Isolation and characterization of a fragment corresponding to the Cgamma2 homology region of human immunoglobin Gl. J Immunol 116:510-517.
215. Rao PE, Kroon DJ. 1993. Orthoclone O KT3. Chemical mechanisms and functional effects of degradation of a therapeutic monoclonal antibody. Pharm Biotechnol 5:135-158.
216. Paborji M, Pochopin NL, Coppola WP, Bogardus JB. 1994. Chemical and physical stability of chimeric L6, a mouse-human monoclonal antibody. Pharm Res 11:764-771.
217. Cordoba AJ, Shyong BJ, Breen D, Harris RJ. 2005. Non-enzymatic hinge region fragmentation of ntibodies in solution. J Chromatogr B Analyt Technol Biomed Life Sci 818:115-121.
218. Smith MA, Easton M, Everett P, Lewis G, Payne M, Riveros-Moreno V, Allen G. 1996. Specific cleavage of immunoglobulin G by copper ions. Int J Pept Protein Res 48:48-55.
219. Allen G, Campbell RO. 1996. Specific cleavage of histidine-containing peptides by copper(II). Int J Pept Protein Res 48:265-273.
220. Friedman M. 1999. Chemistry, biochemistry, nutrition, and microbiology of lysinoalanine, lanthionine, and histidinoalanine in food and other proteins. J Agric Food Chem 47:1295-1319.
221. White HB 3rd, Merrill AH Jr. 1988. Riboflavinbinding proteins. Ann Rev Nutr 8:279-299.
222. Farhangi M, Osserman EF. 1976. Myeloma with xanthoderma due to an IgG lambdamonoclonal anti-flavin antibody. N Engl J Med 294:177-183.
223. Merlini G, Bruening R, Kyle RA, Osserman EF. 1990. The second riboflavin-binding myeloma IgG lambdaDOT. I. Biochemical and functional characterization. Mol Immunol 27:385-394.
224. Zhu X, Wentworth P Jr, Kyle RA, Lerner RA, Wilson IA. 2006. Cofactor-containing antibodies: Crystal structure of the original yellow antibody. Proc Natl Acad Sci USA 103:3581-3585. (Epub 2006 Feb 3528.)
225. Al-Mashikhi SA, Nakai S. 1988. Separation of immunoglobulin and transferrin from blood serum and plasma by metal chelate interaction chromatography. J Dairy Sci 71:1756-1763.
226. Hale JE, Beidler DE. 1994. Purification of humanized murine and murine monoclonal antibodies using immobilized metal-affinity chromatogra-phy. Anal Biochem 222:29-33.
227. Baker BL, Hultquist DE. 1978. A copper-binding immunoglobulin from a myeloma patient. Studies of the copper-binding site. J Biol Chem 253:8444-8451.
228. Dower SK, Dwek RA, McLaughlin AC, Mole LE, Press EM, Sunderland CA. 1975. The binding of lanthanides to non-immune rabbit immunoglobulin G and its fragments. Biochem J 149:73-82.
229. Foote J, Milstein C. 1994. Conformational isomerism and the diversity of antibodies. Proc Natl Acad Sci USA 91:10370-10374.
230. James LC, Roversi P, Tawfik DS. 2003. Antibody multispecificity mediated by conformational diversity. Science 299:1362-1367.
231. Sandin S, Ofverstedt LG, Wikstrom AC, Wrange O, Skoglund U. 2004. Structure and flexibility of individual immunoglobulin G molecules in solution. Structure 12:409-415.
232. aphire EO, Stanfield RL, Crispin MD, Parren W, Rudd PM, Dwek RA, Burton DR, Wilson A. 2002. Contrasting IgG structures reveal xtreme asymmetry and flexibility. J Mol Biol 19:9-18.
233. Minton KW, Karmin P, Hahn GM, Minton AP. 1982. Nonspecific stabilization of stress-susceptible proteins by stress-resistant proteins: A model for the biological role of heat shock proteins. Proc Natl Acad Sci USA 79:7107-7111.
234. Kendrick BS, Carpenter JF, Cleland JL, Randolph TW. 1998. A transient expansion of the native state precedes aggregation of recombinant human inter-feron-gamma. Proc Natl Acad Sci USA 95:14142-14146.
235. Carpenter JF, Kendrick BS, Chang BS, Manning MC, Randolph TW. 1999. Inhibition of stress-induced aggregation of protein therapeutics. Methods Enzymol 309:236-255.
236. Wang W, Singh S, Zeng DL, King K, Nema S. 2007. Antibody structure, instability, and formulation. J Pharm Sci 96:1-26.
237. Philo JS. 2006. Is any measurement method optimal for all aggregate sizes and types? AAPS J 8:E564-E571.
238. Cleland JL, Lam X, Kendrick B, Yang J, Yang TH, Overcashier D, Brooks D, Hsu C, Carpenter JF. 2001. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. J Pharm Sci 90: 310-321.
239. Chen B, Bautista R, Yu K, Zapata GA, Mulkerrin MG, Chamow SM. 2003. Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms. Pharm Res 20:1952-1960.
240. Hartmann WK, Saptharishi N, Yang XY, Mitra G, Soman G. 2004. Characterization and analysis of thermal denaturation of antibodies by size exclusion high-performance liquid chromatography with quadruple detection. Anal Biochem 325: 227-239.
241. Breen ED, Curley JG, Overcashier DE, Hsu CC, Shire SJ. 2001. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation. Pharm Res 18:1345-1353.
242. Maa YF, Nguyen PA, Andya JD, Dasovich N, Sweeney TD, Shire SJ, Hsu CC. 1998. Effect of spray drying and subsequent processing conditions on residual moisture content and physical/ biochemical stability of protein inhalation powders. Pharm Res 15:768-775.
243. Costantino HR, Andya JD, Nguyen PA, Dasovich N, Sweeney TD, Shire SJ, Hsu CC, Maa YF. 1998. Effect of mannitol crystallization on the stability and aerosol performance of a spray-dried pharmaceutical protein, recombinant humanized anti-IgE monoclonal antibody. J Pharm Sci 87:1406-1411.
244. Duddu SP, Dal Monte PR. 1997. Effect of glass transition temperature on the stability of lyophilized formulations containing a chimeric therapeutic monoclonal antibody. Pharm Res 14:591-595.
245. Andya JD, Hsu CC, Shire SJ. 2003. Mechanisms of aggregate formation and carbohydrate excipient tabilization of lyophilized humanized monoclonal antibody formulations. AAPS Pharm Sci 5:E10.
246. Callaghan P, Martin NH. 1963. Optical rotatory dispersion and the conformation of human gamma-globulin. Biochem J 87:225-232.
247. Kravchuk ZI, Vlasov AP, Lyakhnovich GV, Martsev SP. 1994. A stable conformer of IgG obtained by acid treatment: Study by calorimetry and binding of clq component of complement and mono-specific anti_IgG antibodies. Biochemisrty (Moscow) 59:1079-1092.
248. Martsev SP, Kravchuk ZI, Vlasov AP. 1994. Large increase in thermal stability of the CH2 domain of rabbit IgG after acid treatment as evidenced by differential scanning calorimetry. Immunol Lett 43:149-152.
249. Martsev SP, Kravchuk ZI, Vlasov AP, Lyakhnovich GV. 1995. Thermodynamic and functional characterization of a stable IgG conformer obtained by renaturation from a partially structured low pH-induced state. FEBS Lett 361:173-175.
250. Jiskoot W, Bloemendal M, van Haeringen B, van Grondelle R, Beuvery EC, Herron JN, Crommelin DJ. 1991. Non-random conformation of a mouse IgG2a monoclonal antibody at low pH. Eur J Biochem 201:223-232.
251. Buchner J, Renner M, Lilie H, Hinz HJ, Jaenicke R, Kiefhabel T, Rudolph R. 1991. Alternatively folded states of an immunoglobulin. Biochemistry 30:6922-6929.
252. Welfle K, Misselwitz R, Hausdorf G, Hohne W, Welfle H. 1999. Conformation, pH-induced conformational changes, and thermal unfolding of anti-p24 (HIV-1) monoclonal antibody CB 4-land its Fab and Fc fragments. Biochim Biophys Acta 1431:120-131.
253. Kats M, Richberg PC, Hughes DE. 1997. pH-dependent isoform transitions of a monoclonal antibody monitored by micellar electrokinetic capillary chromatography. Anal Chem 69:338-343.
254. Gabrielson JP, Brader ML, Pekar AH, Mathis KB, Winter G, Carpenter JF, Randolph TW. 2007. Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity. J Pharm Sci 96:268-279.
255. Ejima D, Tsumoto K, Fukada H, Yumioka R, Nagase K, Arakawa T, Philo JS. 2007. Effects of acid exposure on the conformation, stability, and aggregation of monoclonal antibodies. Proteins 66: 954-962.
256. Mahler HC, Muller R, Friess W, Delille A, Matheus S. 2005. Induction and analysis of aggregates in a liquid IgGl-antibody formulation. Eur J Pharm Biopharm 59:407-417.
257. Remmele RL Jr, Callahan WJ, Krishnan S, Zhou L, Bondarenko PV, Nichols AC, Kleemann GR, Pipes GD, Park S, Fodor S, Kras E, Brems DN. 2006. Active dimer of Epratuzumab provides insight into the complex nature of an antibody aggregate. J Pharm Sci 95:126-145.
258. Wang L, Hale G, Ghosh R. 2006. Non-size-based membrane chromatographic separation and analysis of monoclonal antibody aggregates. Anal Chem 78:6863-6867.
259. Houde D, Kauppinen P, Mhatre R, Lyubarskaya Y. 2006. Determination of protein oxidation by mass spectrometry and method transfer to quality control. J Chromatogr A 1123:189-198. (Epub 2006 May 2022.)